Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 1;2(2):63-72.
doi: 10.1515/pp-2017-0003. Epub 2017 Apr 7.

Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice

Kurt Van der Speeten  1   2 , Lieselotte Lemoine  3 , Paul Sugarbaker  4
Affiliations
Review

Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice

Kurt Van der Speeten et al. Pleura Peritoneum. .

Abstract

Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are still lacking a much-needed standardization among the various IP chemotherapy treatment modalities used today in clinical practice. Pharmacologic evidence should be generated to answer important questions raised by the myriad of variables associated with IP chemotherapy.

Keywords: bidirectional intraoperative chemotherapy (BIC); early postoperative intraperitoneal chemotherapy (EPIC); hyperthermic intraperitoneal chemotherapy (HIPEC); peritoneal surface malignancy.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Treatment of peritoneal surface malignancy.
See this image and copyright information in PMC

References

    1. Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer 2014;111:1500–8. - PMC - PubMed
    1. Verwaal VJ, Bruin S, Boot H, Van Slooten G, Van Tinteren H. 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426–32. - PubMed
    1. Verwaal VJ, Van Ruth S, De Bree E, Van Sloothen GW, Van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43. - PubMed
    1. Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140–8. - PubMed
    1. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: A prospective randomized phase III study. Ann Surg Oncol 2015;22:1570–5. - PubMed

LinkOut - more resources